Cargando…

The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services

BACKGROUND: A quality improvement programme addressing prescribing practice for acutely disturbed behaviour was initiated by the Prescribing Observatory for Mental Health. METHOD: This study analysed data from a baseline clinical audit conducted in inpatient mental health services in member trusts....

Descripción completa

Detalles Bibliográficos
Autores principales: Paton, Carol, Adams, Clive E, Dye, Stephen, Fagan, Elizabeth, Okocha, Chike, Barnes, Thomas RE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431784/
https://www.ncbi.nlm.nih.gov/pubmed/30565486
http://dx.doi.org/10.1177/0269881118817170
_version_ 1783405985548730368
author Paton, Carol
Adams, Clive E
Dye, Stephen
Fagan, Elizabeth
Okocha, Chike
Barnes, Thomas RE
author_facet Paton, Carol
Adams, Clive E
Dye, Stephen
Fagan, Elizabeth
Okocha, Chike
Barnes, Thomas RE
author_sort Paton, Carol
collection PubMed
description BACKGROUND: A quality improvement programme addressing prescribing practice for acutely disturbed behaviour was initiated by the Prescribing Observatory for Mental Health. METHOD: This study analysed data from a baseline clinical audit conducted in inpatient mental health services in member trusts. RESULTS: Fifty-eight mental health services submitted data on 2172 episodes of acutely disturbed behaviour. A benzodiazepine alone was administered in 60% of the 1091 episodes where oral medication only was used and in 39% of the 1081 episodes where parenteral medication (rapid tranquillisation) was used. Haloperidol was combined with lorazepam in 22% of rapid tranquillisation episodes and with promethazine in 3%. Physical violence towards others was strongly associated with receiving rapid tranquillisation in men (odds ratio 1.74, 1.25–2.44; p<0.001) as was actual or attempted self-harm in women (odds ratio 1.87, 1.19–2.94; p=0.007). Where physical violence towards others was exhibited, a benzodiazepine and antipsychotic was more likely to be prescribed than a benzodiazepine alone (odds ratio 1.39, 1.00–1.92; p=0.05). The data suggested that 25% of patients were at least ‘extremely or continuously active’ in the hour after rapid tranquillisation was administered. CONCLUSION: The current management of acutely disturbed behaviour with parenteral medication may fail to achieve a calming effect in up to a quarter of episodes. The most common rapid tranquillisation combination used was lorazepam and haloperidol, for which the randomised controlled trial evidence is very limited. Rapid tranquillisation prescribing practice was not wholly consistent with the relevant National Institute for Health and Care Excellence guideline, which recommends intramuscular lorazepam on its own or intramuscular haloperidol combined with intramuscular promethazine. Clinical factors prompting the use of rapid tranquillisation rather than oral medication may differ between the genders.
format Online
Article
Text
id pubmed-6431784
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64317842019-04-15 The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services Paton, Carol Adams, Clive E Dye, Stephen Fagan, Elizabeth Okocha, Chike Barnes, Thomas RE J Psychopharmacol Original Papers BACKGROUND: A quality improvement programme addressing prescribing practice for acutely disturbed behaviour was initiated by the Prescribing Observatory for Mental Health. METHOD: This study analysed data from a baseline clinical audit conducted in inpatient mental health services in member trusts. RESULTS: Fifty-eight mental health services submitted data on 2172 episodes of acutely disturbed behaviour. A benzodiazepine alone was administered in 60% of the 1091 episodes where oral medication only was used and in 39% of the 1081 episodes where parenteral medication (rapid tranquillisation) was used. Haloperidol was combined with lorazepam in 22% of rapid tranquillisation episodes and with promethazine in 3%. Physical violence towards others was strongly associated with receiving rapid tranquillisation in men (odds ratio 1.74, 1.25–2.44; p<0.001) as was actual or attempted self-harm in women (odds ratio 1.87, 1.19–2.94; p=0.007). Where physical violence towards others was exhibited, a benzodiazepine and antipsychotic was more likely to be prescribed than a benzodiazepine alone (odds ratio 1.39, 1.00–1.92; p=0.05). The data suggested that 25% of patients were at least ‘extremely or continuously active’ in the hour after rapid tranquillisation was administered. CONCLUSION: The current management of acutely disturbed behaviour with parenteral medication may fail to achieve a calming effect in up to a quarter of episodes. The most common rapid tranquillisation combination used was lorazepam and haloperidol, for which the randomised controlled trial evidence is very limited. Rapid tranquillisation prescribing practice was not wholly consistent with the relevant National Institute for Health and Care Excellence guideline, which recommends intramuscular lorazepam on its own or intramuscular haloperidol combined with intramuscular promethazine. Clinical factors prompting the use of rapid tranquillisation rather than oral medication may differ between the genders. SAGE Publications 2018-12-19 2019-04 /pmc/articles/PMC6431784/ /pubmed/30565486 http://dx.doi.org/10.1177/0269881118817170 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Papers
Paton, Carol
Adams, Clive E
Dye, Stephen
Fagan, Elizabeth
Okocha, Chike
Barnes, Thomas RE
The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services
title The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services
title_full The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services
title_fullStr The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services
title_full_unstemmed The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services
title_short The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services
title_sort pharmacological management of acute behavioural disturbance: data from a clinical audit conducted in uk mental health services
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431784/
https://www.ncbi.nlm.nih.gov/pubmed/30565486
http://dx.doi.org/10.1177/0269881118817170
work_keys_str_mv AT patoncarol thepharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT adamsclivee thepharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT dyestephen thepharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT faganelizabeth thepharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT okochachike thepharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT barnesthomasre thepharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT patoncarol pharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT adamsclivee pharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT dyestephen pharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT faganelizabeth pharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT okochachike pharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices
AT barnesthomasre pharmacologicalmanagementofacutebehaviouraldisturbancedatafromaclinicalauditconductedinukmentalhealthservices